amt-116 car-t cells
Cell therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2022 (NCT05117138)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetImmunity, passive
immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06782334 | Phase 1/Phase 2 (Phase 2) | May 7, 2024 | Multitude Therapeutics Inc. |
| NCT05725291 | Phase 1 | Jun 28, 2023 | Icon Cancer Center, Multitude Therapeutics Inc. |
| NCT05117138 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2022 | Beijing Immunochina Medical Science & Technology Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Multitude Therapeutics Inc. | For profit | 2 | 2 | 2 | 2023 |
| Beijing Immunochina Medical Science & Technology Co., Ltd. | For profit | 1 | 1 | 1 | 2022 |
| Icon Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1